DMRA Damora Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1800315 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,741.0%
TTM EPS YoY179.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-116.1%
ROA-107.4%
ROIC (approx.)-331.3%
Asset turnover—
Leverage & solvency
Liabilities / assets6.9%
Debt / equity0.00x
Current ratio14.80x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.20x
Accruals ratio-85.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $25.48M | $25.54M | $23.78M | $23.32M | $1.42M | $1.47M | $678,000 | $1.01M |
| SG&A expense | $11.39M | $9.45M | $7.03M | $4.07M | $1.74M | $1.96M | $1.92M | $1.70M |
| Operating income | -$36.86M | -$34.99M | -$30.81M | -$201.70M | -$3.16M | -$3.42M | -$2.60M | -$7.10M |
| Pretax income | -$31.99M | -$30.92M | -$27.74M | -$200.69M | -$3.13M | -$3.43M | -$2.53M | -$6.75M |
| Income tax | $0 | $255,000 | $42,000 | $44,000 | $0 | $4,000 | $2,000 | -$8,000 |
| Net income | -$31.99M | -$31.17M | -$27.78M | -$200.74M | -$3.13M | -$3.44M | -$2.53M | -$6.74M |
| EBITDA | -$36.86M | -$34.99M | -$30.81M | -$201.69M | -$3.15M | -$3.42M | -$2.59M | -$7.10M |
| EPS (basic) | -0.40 | -0.39 | -0.62 | — | -2.36 | -2.60 | -1.92 | — |
| EPS (diluted) | -0.40 | -0.39 | -0.62 | — | -2.36 | -2.60 | -1.92 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Weighted avg. shares (diluted) | 61.81M | 61.12M | 34.30M | — | 1.33M | 1.32M | 1.32M | — |
| Banking | ||||||||
| Net interest income | $4.16M | $4.06M | $3.07M | $1.00M | $42,000 | $50,000 | $74,000 | $228,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $349.66M | $540.51M | $532.90M | $257.62M | $7.61M | $10.21M | $11.94M | $14.18M |
| Short-term investments | $178.82M | — | — | $0 | — | — | — | — |
| Current assets | $531.32M | $543.59M | $535.41M | $260.42M | $9.79M | $13.03M | $14.92M | $16.84M |
| PP&E, net | — | — | — | $36,000 | $41,000 | $47,000 | $52,000 | $57,000 |
| Total assets | $532.63M | $543.64M | $535.44M | $260.53M | $10.74M | $13.69M | $15.37M | $17.13M |
| Current liabilities | $35.89M | $27.55M | $23.81M | $20.07M | $2.62M | $2.63M | $1.55M | $1.20M |
| Total liabilities | $36.87M | $27.58M | $23.84M | $20.15M | $2.73M | $2.74M | $1.66M | $1.30M |
| Shareholders' equity | $495.76M | $516.06M | $511.60M | $239.04M | $6.67M | $9.61M | $13.71M | $14.47M |
| Shares outstanding | 61.90M | 61.73M | 60.30M | 1.60M | 1.33M | 1.32M | 1.32M | 1.32M |
| Cash flow statement | ||||||||
| Operating cash flow | -$17.23M | -$21.87M | -$20.60M | $566,000 | -$2.62M | -$2.24M | -$2.44M | -$4.94M |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $5.12M | $29.50M | $295.92M | — | — | — | — | — |
| Depreciation & amortization | $5,000 | $6,000 | $5,000 | $6,000 | $6,000 | $6,000 | $5,000 | $5,000 |
| Stock-based compensation | $9.88M | $10.69M | $3.13M | $483,000 | $164,000 | $172,000 | $179,000 | $308,000 |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.